HOME >> MEDICINE >> NEWS
APA Annual Meeting Media Briefings Schedule

Briefings will be held in the Washington, DC Convention Center, lobby level, Room 17. Please register as press in the APA Communications Center, lobby level, Room 10.

MONDAY, MAY 17; TUESDAY, MAY 18; WEDNESDAY, MAY 19

9:45 - 10:30 am

"Advances in the Treatment of Insomnia"

Martin Scharf, Ph.D., Center for Sleep Disorders, Cincinnati, OH

Sponsored by Wyeth-Ayerst Laboratories/Edelman Worldwide

9:45 - 10:30 am

"Nefazodone - Chronic Depression Study"

Martin Keller, M.D., Chair Department of Psychiatry and Human Behavior, Brown University School of Medicine

Sponsored by Brown University School of Medicine/Bristol-Myers Squibb Company

9:45 - 10:30 am

"Treating Attention Deficit Hyperactivity Disorder: Avoiding the Stigma and Controversy of In-School Dosing"

Steven Pliszka, M.D., University of Texas; Stephen Grcevich, M.D., Case Western Reserve University; National Association of School Nurses; Mary Robertson, President, Children and Adults with Attention Deficit Disorder.

Sponsored by Shire Richwood, Inc./National Association of School Nurses (NASN), Children and Adults with Attention Deficit Disorder (CHADD)

MONDAY, MAY 17; TUESDAY, MAY 18; WEDNESDAY, MAY 19

1:30 - 2:15 p.m.

"The NARSAD Launches $100 Million Campaign for Mental Illness Research"

Allan Tasman, M.D., APA President-Elect; Herbert Pardes, M.D., President, NARSAD Scientific Council, Vice President Health Sciences, Dean Faculty of Medicine, Chairman of the Department of Psychiatry, The College of Physicians and Surgeons, Columbia University

Sponsored by: National Alliance for the Research of Schizophrenia and Depression (NARSAD)

1:30 - 2:15 p.m.

"Is it All in Your Head? The Relationship Be
'"/>

Contact: Melissa Katz
mkatz@psych.org
202-682-6142
American Psychiatric Association
10-May-1999


Page: 1 2 3

Related medicine news :

1. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
2. News tips from the 2005, 54th Annual Scientific Sessions of the American College of Cardiology
3. Annual mammogram, doctor visits are enough for breast cancer follow-up
4. Rebuilding wounded veterans: Annual review of limb loss & prosthetics research
5. Leading researchers in allergic disease to gather for 2005 AAAAI Annual Meeting
6. New studies on Ritalin and Alzheimers Disease highlight ACNP Annual Meeting
7. NYU Child Study Center raises a record $3.4 million at Seventh Annual Child Advocacy Award Dinner
8. New tipifarnib (R115777) data in AML presented at American Society of Hematology Annual Meeting
9. Advances in plasma physics at Annual APS Meeting
10. Advances in plasma physics at Annual APS Meeting
11. Annual vaccination against influenza associated with decreased risk of death in elderly

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: APA Annual Meeting Media Briefings Schedule

(Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
(Date:3/30/2015)... Linda, CA (PRWEB) March 30, 2015 ... challenging due to the use of cellular models that ... not the entirety of the disease. , A ... human cells to precise specifications has created ... to develop environmentally and genetically driven in vitro models ...
(Date:3/29/2015)... Calif. (PRWEB) March 30, 2015 Over ... menopause-related symptoms tied to undiagnosed autoimmune, thyroid, or hormone ... thyroid disorders, has personally treated hundreds of patients dealing ... are unaware of the treatment options for their ailments. ... offers solutions to women living with fatigue, brain fog, ...
(Date:3/29/2015)... Telerad RxDx Multispecialty Healthcare Center, ... Accreditation on 11th January 2015. The accreditation from ... Providers) comes as a true recognition of the ... RxDx., With Telerad RxDx being the first healthcare ... marks a major achievement and a significant step ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
Breaking Medicine News(10 mins):Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 2Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 3Health News:Cellular Dynamics’ Webinar Spotlights Diabetic Cardiomyopathy-in-a-dish Model that May Elucidate Mechanisms for Repair and Regeneration of Heart Muscle Cells 4Health News:How to Turn Mid-life into the Good Life 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences International, ... primary efficacy endpoint in the Phase 3 clinical ... for the treatment of painful diabetic neuropathy did ... showed statistically significant improvement over placebo.  In addition, ... observed.  The results of this trial provide data ...
(Date:3/29/2015)... 2015  Three-month paliperidone palmitate, an investigational atypical ... placebo in patients with schizophrenia, according to a ... in the Journal of the American ... Results of the study served as the basis ... for three-month paliperidone palmitate injection to treat schizophrenia ...
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
Cached News: